13 completed, 4 unknown, 1 withdrawn. 8 Phase 4, 4 Phase 2, 3 Not applicable, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Completed 8 |
| Phase 2 | 4 | Unknown 2, Completed 1, Withdrawn 1 |
| Not applicable | 3 | Completed 2, Unknown 1 |
| Phase 3 | 3 | Unknown 2, Completed 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow this drug Literature Review of Hypromellose Derivatives trials Research Report on Hypromellose Derivatives
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy of Topical Vaginal Oxytocin Gel in Postmenopausal Women With Vulvovaginal Atrophy Oxytocin, Hydroxypropyl methylcellulose - Vaginal Atrophy, Genitourinary Syndrome of Menopause | Phase 3 | Unknown | Oxagon | 244 | 2024-09-01 | 2024-07-23 |
| A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud - Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy | Phase 2 / Phase 3 | Unknown | Wills Eye | 80 | 2023-02-06 | 2024-07-30 |
| Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress Therapies for MGD Vectored thermal pulsation (VTP) therapy, Intense pulsed light with meibomian gland expression (IPL+MGX) therapy, Eyelid Warm Compress Therapy (EW) - Meibomian Gland Dysfunction | Not applicable | Completed | Chinese University of Hong Kong | 374 | 2022-10-08 | 2026-03-19 |
| Single-Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of YJ001 in Healthy Volunteers YJ001 for Spray Use, Placebo of YJ001 for Spray Use - Safety and Tolerability | Phase 1 | Completed | Yuejia Pharmaceuticals (USA), Inc. | 32 | 2022-08-15 | 2023-01-04 |
| Evaluation of Lacrimal Punctal Changes by Anterior Segment Optical Coherence Tomography AS-OCT After Topical Combined Antibiotics and Steroids Treatment in Cases of Inflammatory Punctual Stenosis 5 mg chloramphenicol, 1 mg dexamethasone sodium phosphate, 0.25 mg tetryzoline hydrochloride, 2 mg Hydroxypropyl Methyl Cellulose, 10 mg α-tocopherol acetate and 8 mg macrogol 400)., sodium hyaluronate, polyethylene and propylene glycol based) three times daily for three months - Ophthalmopathy , Lacrimal System | Phase 4 | Completed | Sohag University | 64 | 2020-11-15 | 2021-09-13 |
| Interval Intraocular Pressure in Intravitreal Injection Study Timolol, Travatan, Hypromellose - Glaucoma, Intraocular Pressure | Not applicable | Completed | The University of Hong Kong | 64 | 2019-10-01 | 2021-04-30 |
| Parasitic Ulcer Treatment Trial Pilot Chlorhexidine, Povidone-Iodine, Prednisolone Sodium Phosphate - Acanthamoeba Keratitis | Phase 2 | Completed | University of California, San Francisco | 49 | 2018-01-01 | 2026-05-07 |
| Efficacy and Safety of Cytoflavin® Used in Elderly Patients for the Prevention of Cognitive Decline After Major Surgery Cytoflavin® solution, Cytoflavin® enteric-coated tablet, Placebo solution - Cognitive Dysfunction | Phase 3 | Completed | POLYSAN Scientific & Technological Pharmaceutical Company | 200 | 2017-06-02 | 2023-01-31 |
| Clinical and Structural Outcome of Conventional Versus Accelerated Corneal Collagen Cross-linking (CXL). UV-X 1000 (3 mW/cm²), UV-X 2000 (9 mW/cm²), riboflavin with hydroxypropyl methylcellulose - Keratoconus, Corneal Ectasia | Phase 1 / Phase 2 | Unknown | Oslo University Hospital | 40 | 2012-08-01 | 2016-08-30 |
| Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG travoprost and timolol maleate fixed combination, latanoprost and maleate timolol fixed combination, bimatoprost and timolol maleate fixed combination - Uveitis, Anterior, Cystoid Macular Edema | Phase 4 | Completed | University of Campinas, Brazil | 69 | 2011-10-01 | 2013-11-07 |
| The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients Hydroxypropylmethylcellulose, Carboxymethylcellulose - Dry Eye Syndromes | Phase 4 | Completed | University of Campinas, Brazil | 44 | 2011-03-01 | 2012-07-18 |
| Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in Glaucoma hydroxypropylmethylcellulose, sodium hyaluronate - Ocular Surface Disease, Glaucoma | Not applicable | Unknown | Mahidol University | 120 | 2011-01-01 | 2011-01-27 |
| Assessment of Alcon's Ocular Image Quantification System Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol), Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II) - Allergic Conjunctivitis | Phase 4 | Completed | Alcon Research | 13 | 2010-12-01 | 2012-12-18 |
| Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan® fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops - Glaucoma, Ocular Hypertension | Phase 4 | Completed | Allergan | 121 | 2009-12-01 | 2019-04-24 |
| Efficacy, Tolerability, and Comfort of 0.3% Hypromellose Eyedrops in Patients Undergoing LASIK Surgery Pre-LASIK 0.3% hypromellose, Post-LASIK 0.3% hypromellose - Dry Eye | Phase 4 | Completed | Novartis Pharmaceuticals | 170 | 2009-08-01 | 2020-08-17 |
| Comparison of DisCoVisc and Hydroxypropylmethylcellulose 2% Hyaluronic Acid and hydroxypropylmethylcellulose - Corneal Edema, Intraocular Pressure | Phase 4 | Completed | University of Sao Paulo | 39 | 2009-06-01 | 2011-07-04 |
| Efficacy Study of Ketorolac and HPMC to Treat Dry Eye Ketorolac/HPMC, HPMC, Vehicle - Dry Eye | Phase 2 | Withdrawn | ORA, Inc. | 2009-03-01 | 2024-04-24 | |
| GenTeal in Perioperative Treatment of Laser Assisted in Situ Keratomileusis LASIK Patients 0.3% hypromellose - Corneal Epithelium Defect | Phase 4 | Completed | Augusta University | 80 | 2007-10-01 | 2016-03-07 |
Dry Eye Syndromes (4) · Glaucoma (3) · Acanthamoeba Keratitis (1) · Atrophy (1) · Cognitive Dysfunction (1) · Conjunctivitis, Allergic (1) · Corneal Diseases (1) · Corneal Edema (1) · Eye Diseases (1) · Glaucoma, Open-Angle (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Keratoconus (1) · Macular Edema (1) · Meibomian Gland Dysfunction (1) · Ocular Hypertension (1)
University of Campinas, Brazil (2) · Alcon Research (1) · Allergan (1) · Augusta University (1) · Chinese University of Hong Kong (1) · Mahidol University (1) · Novartis Pharmaceuticals (1) · ORA, Inc. (1) · Oslo University Hospital (1) · Oxagon (1) · POLYSAN Scientific & Technological Pharmaceutical Company (1) · Sohag University (1) · The University of Hong Kong (1) · University of California, San Francisco (1) · University of Sao Paulo (1)
United States (6) · Brazil (3) · Egypt (2) · Hong Kong (2) · India (2) · Russia (1) · Thailand (1)
Alana M Santana, MD (1) · Assem Anwar (1) · AssocProf Pinnita Tanthuvanit, MD (1) · David D Bogorad, M.D (1) · H. Jerome Crampton, MD (1) · Jason Hsu, MD (1) · Jeremy D Keenan, MD (1) · Kelvin KL Chong, MBChB (1) · Tatiana V Kharitonova, MD, PhD (1) · Vital P Costa, MD (1)